X

Trial Profile

A Pilot and Surgical Study of Larotrectinib for Treatment of Children With Newly-Diagnosed High-Grade Glioma With NTRK Fusion

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 01 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Larotrectinib (Primary)
Indications Anaplastic astrocytoma; Diffuse intrinsic pontine glioma; Glioblastoma; Glioma
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Acronyms CONNECT1903

Most Recent Events

20 Apr 2021 Status changed from not yet recruiting to recruiting.
02 Mar 2021 Planned initiation date changed from 1 Feb 2021 to 1 Apr 2021.
14 Dec 2020 Planned initiation date changed from 1 Dec 2020 to 1 Feb 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com